Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SonoSite expands GE patent lawsuit:

This article was originally published in Clinica

Executive Summary

Hand-carried ultrasound developer SonoSite has amended details of its ultrasound patent infringement countersuit against GE. The revised lawsuit now asserts that GE's Vivid and Logiq ultrasound products, certain transducers and the Vivid 7 cart-based system infringe two other patents '566 and '839 related to ultrasound technology with ECG modules and software in a detachable scanhead, in addition to the previous patents mentioned in the original complaint. SonoSite (Bothell, Washington) first filed its counterclaim in July this year in reaction to GE's lawsuit, which alleged that the former's MicroMaxx and Titan imaging systems contravened five patents related to technology that displays blood flow via ultrasound (see Clinica No 1264, p 15).

You may also be interested in...



The Race Is On To Launch COVID-19 Antibody Home-Test In The UK

Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.

Russia May Cap Drug Prices In Fight Against COVID-19

As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products. 

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

Topics

UsernamePublicRestriction

Register

MT049493

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel